Navigation Links
Inovio Biomedical's Partners to Present New Data from Two Cancer,Immunotherapy Clinical Trials

SAN DIEGO--(BUSINESS WIRE)--May 17, 2007 - Inovio Biomedical Corporation (AMEX:INO), focused on the development of DNA-based vaccines for cancers and infectious diseases and a novel alternative to surgery to treat localized cancers, announced today that partners of the company will present new interim data from two phase I clinical trials of plasmid-based immunotherapies using Inovio's electroporation delivery technology at the Third International Conference on DNA Vaccines in Malaga, Spain, being held May 23-25, 2007 at the Torrequebrada Hotel. Dr. Christian Ottensmeier of the University of Southampton will present data relating to a prostate cancer vaccine. Dr. Richard Heller of the University of South Florida and Moffitt Cancer Center will present data on a melanoma immunotherapy study. These clinical studies are assessing safety, tolerability and immune responses of these products in conjunction with Inovio's electroporation-based DNA delivery technologies, which are designed to enhance the potency of immunotherapies including DNA vaccines.

In addition, Dr. Iacob Mathiesen of Inovio will present a general overview of electroporation delivery of immunotherapy products currently in clinical trials; Dr. Alain Rolland of Vical, Inc. will present preclinical data of a DNA vaccine for human cytomegalovirus (CMV) delivered with Inovio technology; Dr. Connie Schmaljohn of USAMRIID at Fort Detrick, MD, will present preclinical data from electroporated DNA vaccines for key biodefense targets; and Dr. Michael Eagan of Wyeth Research will present non-human primate data of an HIV vaccine currently in development with Inovio.

"Inovio has been fortunate to have collaborations with, in our opinion, some of the best scientists in the world to work with us on the development of multiple immunotherapy products delivered using our proprietary electroporation technology," stated Avtar Dhillon, MD, Inovio's CEO. "We look forward to the presentation of this data by our academic, governmental and industrial partners at this important international meeting."

About Inovio's Immunotherapy Products

DNA-based immunotherapy products have the potential to by-pass inherent scientific obstacles of conventional vaccines that prevent their development for cancer and chronic infectious diseases such as HIV and hepatitis C. Pre-clinical data has indicated the potential ability of Inovio's technologies to safely and effectively deliver and significantly enhance the potency of such immunotherapies.

Inovio's DNA-based immunotherapy products consist of DNA plasmids and the Elgen and MedPulser DNA delivery systems. DNA plasmids are designed to express antigens that can induce an immune response specific to a cancer or infectious disease-causing organism. These plasmids are created synthetically and readily manufactured using well-established bacterial fermentation and purification technology. After a plasmid is delivered into muscle or tumor cells, production of the desired antigens may then induce a preventive or therapeutic immune response against the targeted disease. Inovio's advanced electroporation devices facilitate delivery and expression of such immunotherapies and have been shown in primate studies to boost the immune response by orders of magnitude over DNA plasmid alone. Breast cancer, prostate cancer, melanoma, HIV and hepatitis C virus are among the current targets of therapies employing Inovio technology.

Inovio is poised to deliver advanced DNA-based immunotherapies, devices and know-how in this rapidly advancing field. The company is actively licensing its technology to pharmaceutical and biotechnology companies and supporting early stage clinical studies arising from its own research efforts or through academic collaborations.

About Inovio Biomedical Corporation

Inovio Biomedical (AMEX: INO) is focused on commercializing its Selective Electroc hemical Tumor Ablation (SECTA) therapy and development of multiple DNA-based immunotherapies using its delivery platform for gene-based treatments. SECTA is a local ablation therapy for solid tumors designed to selectively kill cancerous cells and minimize cosmetic or functional impacts to predominantly healthy tissue typically treated around a tumor. Inovio is moving its lead product, the MedPulser(R), through pre-marketing studies for head & neck and skin cancers in Europe, where it has CE Mark accreditation, a U.S. Phase III pivotal study for head and neck cancer, and a Phase I/II trial for breast cancer. Inovio's DNA delivery partners include Merck, Wyeth, Vical, University of Southampton, Moffitt Cancer Center, and the U.S. Army, with four DNA-based immunotherapies in Phase I clinical studies. Inovio is a leader in developing human therapeutic applications of electroporation, which uses brief, controlled electrical pulses to increase both cellular uptake of a useful biopharmaceutical and, in the case of gene-based treatments, levels of gene expression. Inovio's technology is protected by an extensive patent portfolio covering in vivo electroporation. More information is available at www.inovio.com.

This press release contains certain forward-looking statements relating to our plans to develop our electroporation drug and gene delivery technology. Actual events or results may differ from our expectations as a result of a number of factors, including the uncertainties inherent in clinical trials and product development programs (including, but not limited to, the fact that pre-clinical results referenced in this release may not be indicative of results achievable from testing in humans), the availability of funding to support continuing research and studies in an effort to prove safety and efficacy of Inovio's technology as a delivery mechanism, the availability or potential availability of alternative therapies or treatments for the conditions targete d by Inovio or its collaborators , including alternatives that may be more efficacious or cost-effective than any therapy or treatment that Inovio and its collaborators hope to develop, evaluation of potential opportunities, issues involving patents and whether they or licenses to them will provide Inovio with meaningful protection from others using the covered technologies, whether such proprietary rights are enforceable or defensible or infringe or allegedly infringe on rights of others or can withstand claims of invalidity and whether Inovio can finance or devote other significant resources that may be necessary to prosecute, protect or defend them, the level of corporate expenditures, assessments of our technology by potential corporate or other partners or collaborators, capital market conditions, and other factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2006, our 10-Q for the three months ending March 31, 2007, and other regulatory filings. There can be no assurance that any product in our product pipeline will be successfully developed or manufactured, or that final results of clinical studies will be supportive of regulatory approvals required to market licensed products.

Contact

Inovio Biomedical Corporation
Bernie Hertel, Investor Relations, 858-410-3101
Jeff Richardson, Media Relations, 805-491-8313


'"/>




Related medicine technology :

1. Vical Interim Clinical Results Demonstrate Safety and Tolerability of Inovio Biomedicals Electroporation DNA Delivery Technology
2. Inovio Biomedical Highlights Enhanced DNA Vaccine Potency with Electroporation DNA Delivery Technology and New Devices at Gene Therapy Meeting
3. Inovio Biomedicals DNA Delivery Technology Shows Safety and Enhances Gene Expression & Tumor Responses in Interim Melanoma Clinical Study Results
4. Inovio: DNA delivery technology shows positive human results
5. Inovio Biomedicals DNA Delivery Technology Significantly Enhances Potency of HIV DNA Vaccine
6. GenoLogics Announces Bioinformatics Partnership with Illumina
7. Novelos Therapeutics Announces Encouraging Results in Ongoing Phase 2 Ovarian Cancer Trial at Dana-Farber/Partners Cancer Care
8. Catalyst Pharmaceutical Partners, Inc. Announces Top-Line Results of Its Bioequivalence Study of CPP-109 (Vigabatrin), the Companys Investigational Drug to Treat Cocaine and Methamphetamine Addiction
9. The Past, Present and Future of HLA Typing
10. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
11. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/27/2017)...  Commended for their devotion to personalized service, SMP Pharmacy ... one in the South Florida Business Journal,s 50 Fastest-Growing Companies, ... list, the national specialty pharmacy has found its niche.  To ... soon be honored by SFBJ as the 2017 Power Leader ... to receive his award in October, Bardisa said of the ...
(Date:9/25/2017)... --  Montrium , an industry leader in powerful ... Trial Master Files & Inspection Readiness Conference ( ... Services has selected eTMF Connect to ... a leading European contract research organization (CRO), will ... enable greater collaboration with sponsors, improve compliance and ...
(Date:9/23/2017)... 22, 2017 Janssen Biotech, Inc. (Janssen) announced ... from the U.S. Food and Drug Administration (FDA) for ... for the treatment of moderately to severely active rheumatoid ... data are needed to further evaluate the safety of ... RA. "We ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... PurhealthRX , a leading Health and Nutrition ... the Purzorb™process to full spectrum CBD oil will revolutionize the rapidly growing CBD market ... can be easily incorporated into liquid products, while reducing costs to end users. , ...
(Date:10/13/2017)... ... October 13, 2017 , ... Apple Rehab Shelton Lakes , ... mock evacuation of the facility as part of a disaster drill on October 3rd. ... EMS and Shelton City Emergency Manager, as well as the Connecticut Long Term ...
(Date:10/13/2017)... ... October 13, 2017 , ... Ellevate Network, the leading ... to advocate for action towards gender equality at their inaugural Summit in New York ... globe, and reached a social audience of over 3 million. To watch the Mobilize ...
(Date:10/13/2017)... ... October 13, 2017 , ... Talented host, actor Rob Lowe, ... in a new episode of "Success Files," which is an award-winning educational program ... investigates each subject in-depth with passion and integrity. , Sciatica occurs when the ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... “America On ... Christian identity. “America On The Brink” is the creation of published author, William ... several great-grandchildren. As a WWII veteran, he spent thirty years in the Navy. ...
Breaking Medicine News(10 mins):